Satori Neuro
Overview
Satori Neuro is an investment firm focused on transformational companies developing innovative solutions for mental and brain health. It targets companies developing breakthrough treatments and disruptive business models, including innovative therapeutics like psychedelic medicine, transcranial magnetic stimulation, virtual/augmented reality protocols, and non-invasive brainwave devices. These treatments are intended to address conditions such as treatment-resistant depression, PTSD, addiction, and neurological disorders.
Portfolio Companies
10
Website
satoricapital.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Gilgamesh Pharmaceuticals | Mar 2026 | Series A | Lead |
| NextSense | Nov 2025 | Series A | Co-investor |
| Nextsense | Nov 2025 | Series A | Co-investor |
| NextSense, Inc. | Nov 2025 | Series A | Co-investor |
| Holobiome | Oct 2024 | Seed | Co-investor |
Key People
Christiana Musk
Operating Partner
Eric W. Bennett
Operating Partner And Advisor
John Ofenloch
Operating Partner
Marc J. Sharpe
Operating Partner
Asher Hochberg
Venture Partner
Amy Kruse
General Partner Chief Investment Officer - Satori Neuro
Karlene Stewart
Director Of Investor Experience
Rugger Burke
Principal, General Counsel, And Investment Committee Member
Pedro G.
Portfolio Manager
Hristina Dishkova
Investor Experience Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.